The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
COMy 2024 | Global disparities in multiple myeloma treatment and clinical trials
Lalit Kumar, MD, MBBS, All India Institute of Medical Sciences, New Delhi, India, addresses global disparities in multiple myeloma treatment and clinical trials. He notes that newer therapies like monoclonal antibodies, bispecifics, and CAR-Ts are largely inaccessible to most patients in Asia and many in the West due to insurance barriers. Dr Kumar stresses the importance of including a diverse patient population in clinical trials to better represent the majority of patients with myeloma. This interview took place at The 10th World Congress on Controversies in Multiple Myeloma (COMy) in Paris, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
